Hilsenbeck SG - Search Results

1

Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results.

Van Pelt AE, Mohsin S, Elledge RM, Hilsenbeck SG, Gutierrez MC, Lucci A Jr, Kalidas M, Granchi T, Scott BG, Allred DC, Chang JC. Van Pelt AE, et al. Among authors: hilsenbeck sg. Clin Breast Cancer. 2003 Dec;4(5):348-53. doi: 10.3816/cbc.2003.n.040. Clin Breast Cancer. 2003. PMID: 14715110

2

Improved methods of estimating mitotic activity in solid tumors.

Hilsenbeck SG, Allred DC. Hilsenbeck SG, et al. Hum Pathol. 1992 Jun;23(6):601-2. doi: 10.1016/0046-8177(92)90312-q. Hum Pathol. 1992. PMID: 1592380 No abstract available.

3

Rising levels of estrogen receptor in breast cancer over 2 decades.

Pujol P, Hilsenbeck SG, Chamness GC, Elledge RM. Pujol P, et al. Among authors: hilsenbeck sg. Cancer. 1994 Sep 1;74(5):1601-6. doi: 10.1002/1097-0142(19940901)74:5<1601::aid-cncr2820740517>3.0.co;2-#. Cancer. 1994. PMID: 8062191

4

p53 is mutated in a subset of advanced-stage prostate cancers.

Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. Bookstein R, et al. Among authors: hilsenbeck sg. Cancer Res. 1993 Jul 15;53(14):3369-73. Cancer Res. 1993. PMID: 8324747

5

WAF1/CIP1 protein expression in human breast tumors.

Diab SG, Yu YY, Hilsenbeck SG, Allred DC, Elledge RM. Diab SG, et al. Among authors: hilsenbeck sg. Breast Cancer Res Treat. 1997 Apr;43(2):99-103. doi: 10.1023/a:1005752829260. Breast Cancer Res Treat. 1997. PMID: 9131264

6

Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer.

Clark GM, Allred DC, Hilsenbeck SG, Chamness GC, Osborne CK, Jones D, Lee WH. Clark GM, et al. Among authors: hilsenbeck sg. Cancer Res. 1997 Dec 15;57(24):5505-8. Cancer Res. 1997. PMID: 9407959

7

Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy.

Diab SG, Hilsenbeck SG, de Moor C, Clark GM, Osborne CK, Ravdin PM, Elledge RM. Diab SG, et al. Among authors: hilsenbeck sg. J Clin Oncol. 1998 May;16(5):1655-60. doi: 10.1200/JCO.1998.16.5.1655. J Clin Oncol. 1998. PMID: 9586875

8

Biomarkers in benign breast disease: risk factors for breast cancer.

Allred DC, Hilsenbeck SG. Allred DC, et al. Among authors: hilsenbeck sg. J Natl Cancer Inst. 1998 Sep 2;90(17):1247-8. doi: 10.1093/jnci/90.17.1247. J Natl Cancer Inst. 1998. PMID: 9731725 No abstract available.

9

p53 mutation and tamoxifen resistance in breast cancer.

Elledge RM, Lock-Lim S, Allred DC, Hilsenbeck SG, Cordner L. Elledge RM, et al. Among authors: hilsenbeck sg. Clin Cancer Res. 1995 Oct;1(10):1203-8. Clin Cancer Res. 1995. PMID: 9815913

10

Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer.

Brown RW, Allred CD, Clark GM, Osborne CK, Hilsenbeck SG. Brown RW, et al. Among authors: hilsenbeck sg. Clin Cancer Res. 1996 Mar;2(3):585-92. Clin Cancer Res. 1996. PMID: 9816207

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

371 results

Search Page

Filters